Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Advances in second messenger and phosphoprotein research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 1372812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• CILO-CLOP Trial: Cilostazol Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke: A Randomized Controlled Multicenter Trial

  2025cites this paper
• Cilostazole versus clopidogrel in acute large-vessel moderate and moderate-to-severe ischemic stroke: a randomized controlled trial

  2025cites this paper
• Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial.

  2025cites this paper
• Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines

  2023cites this paper
• Impaired Platelet Function and Thrombus Formation in PDE5A-Deficient Mice

  2022cites this paper
• Cilostazol for Secondary Stroke Prevention

  2021cites this paper
• Docking and quantitative structure–activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors

  2017cites this paper
• Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives

  2015cites this paper
• platelets through phosphorylation/activation of phosphodiesterase 3A Thrombin regulates intracellular cyclic AMP concentration in human

  2013cites this paper
• Targeting phosphodiesterases in anti-platelet therapy.

  2012cites this paper
• Lonomia obliqua venomous secretion induces human platelet adhesion and aggregation

  2010cites this paper
• Safety and efficacy of cilostazol in the management of intermittent claudication

  2008cites this paper
• Thrombin Regulates Intracellular cAMP Concentration in Human Platelets through Phosphorylation / Activation of PDE 3 A

  2007cites this paper
• Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.

  2007cites this paper
• Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A.

  2007cites this paper
• Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

  2006cites this paper
• Fruit of the jambolan tree (Eugenia jambolana Lam.) and experimental diabetes.

  2005cites this paper
• Platelet Cyclic Adenosine Monophosphate Phosphodiesterases: Targets for Regulating Platelet-Related Thrombosis

  2004cites this paper
• VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors

  2003cites this paper
• Cilostazol

  2003cites this paper
• Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets

  2003cites this paper
• Differential Regulation of Human Platelet Responses by cGMP Inhibited and Stimulated cAMP Phosphodiesterases

  2002cites this paper
• Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.

  2001cites this paper
• Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence.

  2001cites this paper
• Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.

  2000cites this paper
• Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.

  2000cites this paper
• Inactivation of platelet PDE2 by an affinity label: 8-[(4-bromo-2, 3-dioxobutyl)thio]cAMP.

  2000cites this paper
• Design and organization of the cilostazol stroke prevention study

  2000cites this paper
• Cyclic Nucleotide Hydrolysis in Bovine Aortic Endothelial Cells in Culture: Differential Regulation in Cobblestone and Spindle Phenotypes

  2000cites this paper
• Cilostazol prevents impairment of slow axonal transport in streptozotocin-diabetic rats.

  2000cites this paper
• Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1)

  1999cites this paper
• Cilostazol

  1999cites this paper
• Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.

  1999cites this paper
• Platelet Cyclic Nucleotide Phosphodiesterases

  1999cites this paper
• Bronchoprotective Effect of an Intrabronchial Administration of Cilostazol Powder and a Nebulized PDE1 and PDE4 Inhibitor KF19514 in Guinea Pigs

  1998cites this paper
• Adenosine 5'-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins.

  1998cites this paper
• Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats.

  1998cites this paper
• Aggregation of Human Blood Platelets by Remnant Like Lipoprotein Particles of Plasma Chylomicrons and Very Low Density Lipoproteins

  1997cites this paper
• Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo.

  1997cites this paper
• Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor

  1997cites this paper
• Section Review Cardiovascular & Renal: Phosphodiesterase 5 inhibitors in development for cardiovascular therapy

  1996cites this paper
• 2 – Analysis of PDE Isoenzyme Profiles in Cells and Tissues by Pharmacological Methods

  1996cites this paper
• Platelet cAMP and cGMP Phosphodiesterases.

  1995cites this paper
• Section Review: Cardiovascular & Renal: Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases

  1995cites this paper
• Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family).

  1995cites this paper
• cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells.

  1995cites this paper